Journal of Clinical Endocrinology & Metabolism, Vol 60, 1093-1096, Copyright © 1985 by Endocrine Society

ARTICLES

Genetic transmission of tumoral calcinosis: autosomal dominant with variable clinical expressivity

KW Lyles, EJ Burkes, GJ Ellis, KJ Lucas, EA Dolan and MK Drezner

Tumoral calcinosis is a rare inherited metabolic disorder characterized by hyperphosphatemia, elevated serum 1,25-dihydroxyvitamin D levels and periarticular cystic and solid calcifications. Based on previous investigations, the inheritance of this disorder has been postulated to be autosomal recessive. This interpretation was based on finding clinically affected subjects in only single generations of kindreds. We investigated four generations of an affected kindred and found nine subjects with the disease. A unique dental lesion which is specific for this disorder and serves as a phenotypic marker was identified in two generations of the kindred. In all affected subjects, elevated serum 1,25-dihydroxyvitamin D levels were found, although each member did not have the classical clinical findings of tumoral calcinosis. The possibility that this disorder may be variably expressed and have multiple formes frustes has not been previously considered. Using the unique dental lesion as well as the classical clinical and biochemical abnormalities, we found that in this kindred, tumoral calcinosis is transmitted in an autosomal dominant mode, with variable clinical expressivity.

This article has been cited by other articles:

				H. Olauson, T. Krajisnik, C. Larsson, B. Lindberg, and T. E Larsson A novel missense mutation in GALNT3 causing hyperostosis-hyperphosphataemia syndrome. Eur. J. Endocrinol., June 1, 2008; 158(6): 929 - 934. [Abstract] [Full Text] [PDF]

				S. Ichikawa, V. Guigonis, E. A. Imel, M. Courouble, S. Heissat, J. D. Henley, A. H. Sorenson, B. Petit, A. Lienhardt, and M. J. Econs Novel GALNT3 Mutations Causing Hyperostosis-Hyperphosphatemia Syndrome Result in Low Intact Fibroblast Growth Factor 23 Concentrations J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1943 - 1947. [Abstract] [Full Text] [PDF]

				K. M. Olsen and F. S. Chew Tumoral calcinosis: pearls, polemics, and alternative possibilities. RadioGraphics, May 1, 2006; 26(3): 871 - 885. [Abstract] [Full Text] [PDF]

				E. A. Imel and M. J. Econs Fibroblast Growth Factor 23: Roles in Health and Disease J. Am. Soc. Nephrol., September 1, 2005; 16(9): 2565 - 2575. [Full Text] [PDF]

				S. Ichikawa, K. W. Lyles, and M. J. Econs A Novel GALNT3 Mutation in a Pseudoautosomal Dominant Form of Tumoral Calcinosis: Evidence That the Disorder Is Autosomal Recessive J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2420 - 2423. [Abstract] [Full Text] [PDF]

				A. Benet-Pages, P. Orlik, T. M. Strom, and B. Lorenz-Depiereux An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia Hum. Mol. Genet., February 1, 2005; 14(3): 385 - 390. [Abstract] [Full Text] [PDF]

				W. T. Lowrance, J. M. Skoner, M. S. Richardson, and M. B. Gillespie Pathology Quiz Case 2 Arch Otolaryngol Head Neck Surg, December 1, 2002; 128(12): 1427 - 1427. [Full Text] [PDF]

				S. Varma, A. Bhansali, S S Gill, S. Kumari, and S. Singh Peri-articular `hard tumours' in soft tissues Postgrad. Med. J., August 1, 1999; 75(886): 492 - 495. [Full Text]